On March 14, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, reported that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference (Press release, Aldeyra Therapeutics, MAR 14, 2022, View Source [SID1234610055]). The conference is being conducted in a virtual format March 15-17, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Brady’s conversation with Justin Kim, Senior Analyst, Biotech Equity Research at Oppenheimer, is scheduled to begin at 11:20 a.m. ET Wednesday, March 16, 2022. A webcast of the presentation can be accessed on the Investors & Media section of the Aldeyra website at View Source Following the presentation, the webcast will be archived for 90 days.